Recombinant Chimeric antibody to Human CA9. The drug candidate REDECTANE® (INN: 124I-Girentuximab) is based on an antibody and is being developed for the pre-surgical diagnosis of clear cell Renal Cell Cancer. REDECTANE® is the radioactively labelled form of the antibody Girentuximab. The monoclonal antibody Girentuximab binds specifically to a protein structure on the cell surface of malignant tumour cells. This protein structure, called Carbonic anhydrase IX (also CA-IX, MN or G250 antigen) is found on over 90 % of clear cell renal cell carcinomas, but not on normal renal tissue.
Figure 1 G250 (Girentuximab) monoclonal antibody (MAb) binding properties ‑ domain specificity.
The target domain of the parental murine mG250 Mab was determined by ELISA.
Zatovicova, M., Jelenska, L., Hulikova, A., Ditte, P., Ditte, Z., Csaderova, L., ... & Pastorek, J. (2014). Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model. international journal of oncology, 45(6), 2455-2467.
Figure 2 G250 (Girentuximab) monoclonal antibody (MAb) binding properties ‑ domain specificity.
The CA domain specificity of G250 MAb was confirmed by immunoprecipitation of the full‑length human carbonic anhydrase gene (CA9) and its deletion variants from biotinylated cell extracts with G250 Mab as well as with M75 and V/10 Mabs as controls.
Zatovicova, M., Jelenska, L., Hulikova, A., Ditte, P., Ditte, Z., Csaderova, L., ... & Pastorek, J. (2014). Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model. international journal of oncology, 45(6), 2455-2467.
Figure 3 Monoclonal antibody (MAb) specificly binds to target.
The competitive ELISA was performed with the biotin-labeled G250 competing for binding to CA IX antigen from MDCK-CA9 cell extract against increasing concentrations of the simultaneously added non-labeled CA IX-specific antibodies.
Zatovicova, M., Jelenska, L., Hulikova, A., Ditte, P., Ditte, Z., Csaderova, L., ... & Pastorek, J. (2014). Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model. international jonal of oncology, 45(6), 2455-2467.
Figure 4 G250 monoclonal antibody (MAb) binding properties - antigen/isoform specificity.
Ability of mG250 MAb to recognize the full-length CA (FL) and its ectodomain (ECD), but not the alternatively spliced variant (hAS) was demonstrated by immunoprecipitation using the extracts and media from CGL3 cells naturally expressing CA and from the transfected MDCK cells (MDCK-hAS), followed by the western blotting with the M75 MAb.
Zatovicova, M., Jelenska, L., Hulikova, A., Ditte, P., Ditte, Z., Csaderova, L., ... & Pastorek, J. (2014). Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model. international jol of oncology, 45(6), 2455-2467.
Figure 5 cG250 monoclonal antibody (MAb) binding in presence of carbonic anhydrase (CA) inhibitor homosulfanilamide.
cG250 binding to CGL3 cells in absence and presence of the inhibitor was also visualized by immunofluorescence.
Zatovicova, M., Jelenska, L., Hulikova, A., Ditte, P., Ditte, Z., Csaderova, L., ... & Pastorek, J. (2014). Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model. international jol of oncology, 45(6), 2455-2467.
Figure 6 G250 monoclonal antibody (MAb) internalization: co-localization with carbonic anhydrase protein (CA IX) and effects of hypoxia, pH and cell density.
cG250-CA IX co-localization was evaluated in normoxic MDCK-CA9 cells subjected to different cG250 internalization periods.
Zatovicova, M., Jelenska, L., Hulikova, A., Ditte, P., Ditte, Z., Csaderova, L., ... & Pastorek, J. (2014). Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model. international jol of oncology, 45(6), 2455-2467.
Figure 7 In vivo anticancer effects of mG250 monoclonal antibody (MAb) on tumour growth and serum levels of shed carbonic anhydrase protein (CA IX) ectodomain (ECD).
Graph illustrating volumes of tumours grown from subcutaneously xenografted HT-29 cells in mice subjected to either immediate or delayed onset of treatment with mG250 MAb in comparison to non-treated controls (n=20 per group) as calculated from caliper measurements.
Zatovicova, M., Jelenska, L., Hulikova, A., Ditte, P., Ditte, Z., Csaderova, L., ... & Pastorek, J. (2014). Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model. international joof oncology, 45(6), 2455-2467.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-707 | Anti-CAIX/CA9 Recombinant Antibody (Girentuximab) | WB, FuncS, IF, Neut, ELISA, FC, IP | IgG1 - kappa |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBZ-017 | Mouse Anti-CA9 Recombinant Antibody (clone M75); scFv Fragment | WB, FuncS | Mouse scFv |
TAB-1458CL-S(P) | Anti-Human CA9 Recombinant Antibody (MSC3); scFv Fragment | FC | Human scFv |
HPAB-0104-LSX-S(P) | Human Anti-CA9 Recombinant Antibody; scFv Fragment (HPAB-0104-LSX-S(P)) | ELISA | Human scFv |
HPAB-0105-LSX-S(P) | Human Anti-CA9 Recombinant Antibody; scFv Fragment (HPAB-0105-LSX-S(P)) | ELISA | Human scFv |
HPAB-0782-CN-S(P) | Human Anti-CA9 Recombinant Antibody (clone G119); scFv Fragment | ELISA, FC | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1454CL | Anti-Human CA9 Recombinant Antibody (G250) | Cyt | |
TAB-1455CL | Anti-Human CA9 Recombinant Antibody (S239D/I332E) | SPR | |
TAB-1456CL | Anti-Human CA9 Recombinant Antibody (MSC1) | ELISA, FC, Inhib | Fully human antibody |
TAB-1457CL | Anti-Human CA9 Recombinant Antibody (MSC2) | ELISA, FC, Inhib | Fully human antibody |
TAB-1459CL | Anti-Human CA9 Recombinant Antibody (MSC4) | ELISA, FC, Inhib | Fully human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1458CL | Anti-Human CA9 Recombinant Antibody (MSC3) | FC | Human IgG1 |
MRO-0229-CN | Rabbit Anti-CA9 Recombinant Antibody (clone CBACN-083) | WB, IHC | Rabbit IgG |
ZG-0735F | Mouse Anti-CA9 Recombinant Antibody (clone 66.4.C2) | IHC-P, IHC-Fr | Mouse IgG2b |
ZG-0578J | Rabbit Anti-CA9 Recombinant Antibody (clone 4F12) | ELISA, IHC | Rabbit IgG |
VS3-QX140 | Mouse Anti-CA9 Recombinant Antibody (clone 5B5-B10-A2) | WB, IHC, ICC, FC, ELISA | Mouse IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-0427 | Hi-Affi™ Rabbit Anti-CA9 Recombinant Antibody (clone DS427AB) | IHC-P, WB | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0104-LSX-F(E) | Human Anti-CA9 Recombinant Antibody; Fab Fragment (HPAB-0104-LSX-F(E)) | ELISA | Human Fab |
HPAB-0105-LSX-F(E) | Human Anti-CA9 Recombinant Antibody; Fab Fragment (HPAB-0105-LSX-F(E)) | ELISA | Human Fab |
HPAB-0355-CN-F(E) | Mouse Anti-CA9 Recombinant Antibody; Fab Fragment (HPAB-0355-CN-F(E)) | WB, ELISA, FC | Mouse Fab |
HPAB-0356-CN-F(E) | Mouse Anti-CA9 Recombinant Antibody; Fab Fragment (HPAB-0356-CN-F(E)) | WB, ELISA, FC | Mouse Fab |
HPAB-0357-CN-F(E) | Mouse Anti-CA9 Recombinant Antibody; Fab Fragment (HPAB-0357-CN-F(E)) | WB, ELISA, FC | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-H43 | Afuco™ Anti-CA9 ADCC Recombinant Antibody (Girentuximab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
There are currently no Customer reviews or questions for TAB-H43. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.